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Abstract
This paper presents the existing legal frameworks, professional guidelines and other documents related to the
conditions and extent of the disclosure of genetic information by physicians to at-risk family members. Al-
though the duty of a physician regarding disclosure of genetic information to a patient’s relatives has only been
addressed by few legal cases, courts have found such a duty under some circumstances. Generally, disclosure
should not be permitted without the patient’s consent. Yet, due to the nature of genetic information, exceptions
are foreseen, where treatment and prevention are available. This duty to warn a patient’s relative is also
supported by some professional and policy organizations that have addressed the issue. Practice guidelines with
a communication and intervention plan are emerging, providing physicians with tools that allow them to assist
patients in their communication with relatives without jeopardizing their professional liability. Since guidelines
aim to improve the appropriateness of medical practice and consequently to better serve the interests of
patients, it is important to determine to what degree they document the ‘best practice’ standards. Such an
analysis is an essential step to evaluate the diﬀerent approaches permitting the disclosure of genetic information
to family members.
Introduction
The use of genetic tests to identify individuals with an
increased risk of hereditary diseases has generated legal
and ethical controversies in relation to the duty of
physicians to warn family members of their genetic risks.
Indeed, when it comes to potentially preventable or
treatable hereditary diseases, it can be very important
for individuals to be informed of a family member’s
genetic test result and thus of their own genetic risk [1].
However, in certain circumstances, the tested person
might want to withhold this diagnosis from his spouse,
children and other blood relatives [3]. In this case, there
arises the problem of how patients and their doctors
should mediate the patients’ ‘right to keep their genetic
information secret’ with family members’ ‘right to know
about their genetic risks’. This issue is particularly
problematic for physicians who hold such information
and are aware of the individuals’ refusal to share
information with at-risk family members.
In the United States, three claims for negligence
alleging the failure to disclose genetic information to the
patients’ relatives have been brought against physicians
[4, 5, 6]. A duty to warn family members of their
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potential risk of suﬀering from hereditary syndromes
was recognized by the courts. In parallel, an increasing
number of professional organizations and government
agencies have identiﬁed disclosure of genetic informa-
tion to at-risk family members as an important issue. In
certain cases, however, they adopted diﬀerent view-
points and recommended whether to disclose to family
members without or with the patient’s consent, whether
not to disclose at all, whether special consideration be
made for informing family members.
This paper presents the existing legal frameworks,
professional guidelines and other documents related to
the conditions and extent of the disclosure of genetic
informationbyphysicians to at-risk familymembers.This
paper examines the commonality and differences between
the positions taken in order to discern general trends.
Practical frameworks to guide physicians for resolving
‘difﬁcult’ situations are proposed. Since guidelines aim to
improve the appropriateness of medical practice and
consequently to better serve the interests of patients, it is
important to determine to what degree they document the
‘best practice’ standards. Such an analysis is an essential
step to evaluate the different approaches permitting the
disclosure of genetic information to family members.
Methods
We made a structured review of guidelines published
from 1987 through April 2004 identiﬁed by a PUBMED,
HUMGEN as well as global Internet search using the
following terms: duty, warn, disclosure, notiﬁcation,
guidelines, statement, position paper, protocol, recom-
mendations, opinion, policy, genetic, testing, conﬁdenti-
ality, family members and relatives. Names of
professional organizations and government agencies
involved in practice guideline activity were also included
as search terms. Articles about guidelines were searched
for additional published guidelines. In addition, we
searched citations of key papers and recent reviews of
the subject. We reviewed legal decisions pertaining to a
physician’s duty towarn in theUnited States andCanada.
Retrieved documents were considered guidelines if
they made speciﬁc recommendations for practice. Since
few guidelines were published prior to 1987, we evaluated
only guidelines published in odd-numbered years from
1987 through April 2004. We analyzed 62 guidelines
produced by 42 different developers. Of the guidelines
examined, seven were produced by international organi-
zations (HUGO, UNESCO, WHO, WMA), eight by
regional bodies (Council of Europe, European Parlia-
ment, GAEIB, HGSA), and 47 by national instances
(Australia, Austria, Canada, Denmark, France, Ger-
many, Japan, Switzerland, The Netherlands, UK, USA).
Results
The duty to warn a patient’s relative raises conﬂicting
ethical obligations. Physicians must weigh their duty to
preserve their patient’s privacy and autonomy against
their obligation to prevent harm and promote the
beneﬁcence of family members [7, 8]. In this process, a
second, related dilemma is that physicians’ duty to
promote others’ beneﬁcence may be outweighed by
family members’ autonomy and their own right not to
know about their genetic conditions.
Respect for patient’s privacy
Since the Hippocratic Oath, physicians have been bound
by a duty to protect the privacy of their patients. This
duty rests on three premises: (1) individual autonomy,
(2) shared respect for conﬁdentiality, (3) beneﬁts to both
individuals and the society [9]. Ethical guidelines and
recommendations issued by professional and govern-
mental agencies in the medical ﬁeld have emphasized the
fundamental value of conﬁdentiality in the patient–
doctor relationship. This ethical duty has evolved to a
legal duty in most jurisdictions and most countries have
enacted legislation to protect conﬁdentiality of personal
and/or medical information. However, with a few
exceptions, such as Austria,1 Israe¨l,2 the United States,3
Denmark,4 the province of Manitoba in Canada,5 and
Switzerland,6 no enacted7 legislation relates speciﬁcally
to the protection of personal genetic data. Therefore, it
is general data protection legislation that may apply to
the protection of conﬁdentiality of genetic information.
Nevertheless, medical conﬁdentiality is not an absolute
principle and has never been so, even in the traditional
physician–patient relationship [10]. First, physicians may
disclose information to a third party when speciﬁcally
authorized by the patient. Second, the law may mandate
physicians to disclose patients’ medical information
without their consent for use in judicial proceedings or
in cases of transmissible diseases, child abuses, domestic
violence or conditions that could constitute a danger for
the safety of the public. It is in this last exception that the
roots of a duty to warn third parties in the context of the
physician–patient relationship were found.
Right not to know
A further complication resulting from the duty to warn
is that some family members may wish not to be
informed of their genetic risks. The ethical principle of
non-maleﬁcence stipulates that one should refrain from
taking actions that will result in a harmful outcome.
According to this principle, the decision to inform
family members of their genetic risks should be weighed
against all the possible harm that may result from such a
disclosure. Potential for harm incurred from such
disclosure may include psychological, social or ﬁnancial
damages. There are positive aspects to ignorance,
particularly in a disease where there is no prospect of
prevention or treatment.
On the other hand, when a prevention or treatment is
available, is it possible to objectively consider the rela-
tives’ wish to remain ignorant of that information? There
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are two contexts in which the right not to know can be
discussed. The ﬁrst is where an individual knows that he
has an increased prior risk but reserves the right not to
seek extra information; the second is where an individual
has no knowledge of prior risk [11]. In the ﬁrst case, few
would seriously question the individual’s right not to
know and an unsolicited disclosure would be rarely
justiﬁed. It would also be rare for close relatives not to
know anything about each other’s serious medical con-
ditions, and often they have heard something when the
disease is hereditary. That explains why in Denmark,
relatives who underwent a genetic test for 1-antitrypsin
deﬁciency supported the disclosure of familial informa-
tion; because of the condition’s hereditary nature, they
were also more likely to endorse communication with
relatives without the patient’s consent [12].
In the second case, an unsolicited disclosure to
someone ignorant of its risk status might be justiﬁed;
it should be based on the principle of maximizing
beneﬁt and minimizing harm [13, 14]. It has been argued
that people cannot be expected to make autonomous
choices about their future without having all the
relevant information at their disposal and that declining
to give them this information is indefensibly paternal-
istic [15]. In this view, there is a presumption that
knowledge is to be preferred to ignorance, particularly
when matters of reproductive choice are involved or if
prevention and treatment are available. Consequently,
limits may occur where there are harmful eﬀects on the
patient or for the protection of another person’s life [16,
17, 18].
Promotion of patient’s beneﬁcence
The duty to warn family members of their genetic risks:
legal aspects
A duty to warn third parties in the context of the
physician–patient relationship has been recognized in a
leading case in the United States [19], creating a cause of
action when physicians fail to inform at-risk third
parties of information gathered during a therapeutic
relationship.8 The duty to warn has been interpreted as a
duty to act to prevent foreseeable harm.9
In regard to genetic diseases, the jurisdictions that have
considered genetic cases (Florida [4], New Jersey [5] and
Minnesota [6]) have recognized a legal duty of a physician
towarn the relatives of his patients.10 The courts balanced
the patient’s right to conﬁdentiality and the beneﬁts this
brings against the right of the unaware. The Pate court
recognized the need for conﬁdentiality and determined
that a physician can fulﬁll his duty by notifying the patient
of any genetic ramiﬁcations of the disease to his family
members, while theSafer court held that a physician has a
duty to directly warn those third parties known to be at
risk of avoidable harm from a genetically transmissible
condition. The three-judge panel in the Safer case
concluded that ‘there is no essential diﬀerence between
the type of genetic threat at issue here and the menace of
infection, contagion, or a threat of physical harm’ [5]. The
Molloy court held that ‘a physicianwho undertakes to test
for and diagnose a genetic disorder in an existing child
owes a duty of care to the biological parents of the child
when it is reasonably foreseeable that the parents would
be injured if the testing and diagnosis are negligently
performed’ [6]. However, these decisions do not provide
American physicians with a clear statutory ruling on this
issue and to date, they have not been followed in other
jurisdictions of the United States.
In other countries, with a few notable exceptions such
as Austria11 and France,12 the legal system does not
provide more guidance on the responsibilities of physi-
cians towards at-risk relatives in the context of genetic
testing. Most European jurisdictions, evoking profes-
sional secrecy, require the free consent of the individual
before relevant personal information is passed on to
relatives [20]. Yet, general personal data protection
legislation usually speciﬁes the exceptional circumstances
in which personal information may be disclosed without
the individual’s consent. These exceptions include the
cases where disclosure is required to prevent or lessen a
serious and imminent threat to the health and safety of
third parties.13 Nevertheless, how this legal exception
may apply in cases of risks resulting from genetic diseases
remains highly controversial and unclear in Europe as
well as in North America and Australia.
The duty to warn family members of their genetic risks:
guidelines
Guidelines issued by professional organizations and
governmental advisory agencies on this issue are of
primordial importance. They constitute an important
part of the regulatory context within which clinical
genetics is practiced. Although such guidelines, codes of
ethics and recommendations have no legal standing in
most countries, they may be used as evidence of the
accepted standards of professional practice [21].
The duty of a physician regarding disclosure of a
genetic disease to a patient’s relative has been considered
by several professional organizations as well as by
government agencies (Table 1). However, their recom-
mendations vary and often leave room for diﬀerent and
somehow subjective interpretations for the health care
providers faced with this issue.
Some organizations authorize the disclosure of genetic
information to family members with the patient’s con-
sent only and do not explicitly address any exception to
the traditional principle of conﬁdentiality in this respect.
Others speciﬁcally address the circumstances in which
such a disclosure may occur without the patient’s
consent. Conversely, a few organizations advise against
any direct communication between a physician and his
patients’ relatives.
Direct communication between physician and patient’s
relatives not supported
Some instances advise against any direct communication
between physicians and patients’ relatives. Consequently,
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they do not support disclosure of genetic information by
the physician to family members, and this, to a certain
extent, even with the patient’s consent. This position is
grounded on two main ideas. First, the conﬁdentiality of
the results of genetic tests is an absolute ethical imperative
and no exception should ever occur. Second, the duty to
inform relatives of their genetic risks is a moral obligation
that is owed by the patient him/herself and not by
physicians. Therefore, physicians should not deal with
family members.
Such a position prevails in France, where, as men-
tioned above, legislation considerably limits any direct
communication between physicians and third parties.
French law even mandates physicians not to intrude into
their patients’ ‘family business’, unless they have profes-
sional reasons to do so.14 Thus, accordingly, the CCNE
(1991, 2001, 2003) supports a strict observance of
medical conﬁdentiality and explicitly states that it is up
to the person tested, and to this person only, to inform
his/her family members of their genetic risks, while
physicians should content themselves with advising their
patients (CCNE, 2003). In the same vein, the Danish
Council of Ethics believes that the disclosure of genetic
information to a relative is best done by having the
decision made by the patient: when dealing with personal
sensitive information, ‘no unsolicited approach may be
made by the health authorities in the case of an
examination that may show any hereditary disease in
the family. This should also be the case in situations
where it can have serious consequences’ (DCE, 1993).
Meanwhile, the Greek National Bioethics Commission
stresses that all patients who know about their genetic
risk ‘must assume responsibility for informing any third
persons involved’ (GNBC, 2002).15 However, in cases
where the patient has decided not to know about his/her
own results, a physician could disclose information to the
patient’s relatives when ‘absolutely necessary’ (GNBC,
2002). Finally, the American Society of Clinical Oncol-
ogy and the American Medical Association do not seem
to support any direct contact between physicians and
Table 1. Disclosure of genetic information to family members by physicians.
s With patient’s
consent only
Without patient’s
consent, under
exceptional
circumstances
Special
considerations
International WMA, 19921 UNESCO, 1997,3 2004 4
WHO, 19982 HUGO, 1996 5
Regional European Parliament, 1990 6 European Parliament, 2001 9
GAIEB (EGE), 1996 7 Council of Europe, 1992,10 199711
HGSA, 1999 8 European Commission, 2004 12
National
Australia NHMRC, 1999 13 AMA, 200415 NHMRC, 2000 17
AMA, 1998 (2000, 2002) 14 CCV, 1997 & NHMRC,
1999 16
Canada TCPS, 1998 18 CCOHTA, 1999 20 Ontario Provincial
Advisory
Committee, 200125
CCFF, 2002 19 SCC, 1991 21 CMA, 1998 26
RMGA, 2000 22 CBAC, 2001 27
CMA, 1996,23 200024
Denmark DCE, 1993 28 DCE, 2001 29
France CCNE, 1991,
2001, 200330
GGC & FNCLCC, 2002 31
Germany GSHG, 1996, 2001 32
Greece GNBC, 2002 33
Italy CNB, 1999 34
Japan JSHG, 1994 35
JSHG, 1995 36
Switzerland SAMS, 199337
United Kingdom HCSTC, 199538 BSHG, RCP & RCP, 200340
GIG, 200139 HGC, 200241
BMA, 199842
GMC, 199643
GIG, 199844
NCB, 200045
United States ASCO, 2003 46 NSGC, 1991, rev. 200248 American President’s
Commission, 198350
AMA, 200347 GLRGG, 199349 IOM, 199451
ASHG/ACMG, 199552
ASHG, 199853
NHGRI, 199754
Notes: Refer section on Notes for Table 1.
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their patients’ relatives either. ASCO strongly believes
that a ‘cancer care provider’s obligations (if any) to at-
risk relatives are best fulﬁlled by communication of
familial risk to the person undergoing testing (...)’
(ASCO, 2003). AMA only states that ‘physicians should
identify circumstances under which they would expect
patients to notify biological relatives of the availability of
information related to risk of disease’. However, AMA
believes that physicians should ‘make themselves avail-
able to assist patients in communicating with relatives to
discuss opportunities for counseling and testing (...)’
(AMA, 2003).
Disclosure with the patient’s consent only
Most guidelines do not preclude direct communication
between a physician and her/his patient’s relatives.
However, some of them limit such communication and
the disclosure of genetic information to family members
in cases where the consent of the patient has been
obtained. Such positions emphasize the idea that conﬁ-
dentiality can never be infringed without the patient’s
consent, whatever the circumstances. That is the position
of the European Parliament (1990) and the former
Group of Advisers to the European Commission on the
Ethical Implications of Biotechnology16 (1996), as well
as the Human Genetics Society of Australasia (1999). At
the national level, this viewpoint is clearly supported by
the British House of Common Science and Technology
Committee which states that ‘if counseling cannot
persuade someone to consent sharing information with
their relatives, the individual’s decision to withhold
information should be paramount’ (HCSTC, 1995). In
other national recommendations, disclosure of genetic
information within families is described as a moral
obligation owed by the patient and disclosure is permit-
ted with the consent of the data subject only (Canada:
CCFF (2002); Australia: NHRMC (National State-
ment..., 1999); Switzerland: SAMS (1993); UK: GIG
(2001); USA: GLRGG (1993), NSGC (1991, 2002);
Italy: CNB (1999)).
Disclosure without the patient’s consent
Most guidelines also allow the disclosure of genetic
information to family members without the patient’s
consent. However, certain conditions should be re-
spected. Already, in 1983, the American President’s
Commission for the Study of Ethical Problems in
Medicine and Biomedical and Behavioural Research
deﬁned four conditions that must be met before patient
genetic information is disclosed without consent: ‘(1)
reasonable efforts to elicit voluntary consent to disclo-
sure have failed; (2) there is a high probability both that
harm will occur if the information is withheld and that
the disclosed information will actually be used to avert
harm; (3) the harm that identiﬁable individuals would
suffer is serious; and (4) appropriate precautions are
taken to ensure that only the genetic information needed
for diagnosis and/or treatment of the disease in question
is disclosed’. Ten years latter, the Committee on
Assessing Genetic Risks of the Institute of Medicine
[24] added another condition: ‘there is no other reason-
able way to avert the harm’.17 However, neither group
supported a legal duty to inform relatives, but they
argued for an ethical duty and legal permission (vs legal
obligation) to inform in certain cases.
In balancing the duty to inform against the right to
conﬁdentiality, the serious nature of the threat has been
considered in most documents that authorize disclosure
without patients’ consent. The WMA’s position in its
Declaration on the Human Genome Project [1992], is
that ‘even if family members of the patient may be at
risk, medical secrecy has to be kept unless there is a
serious harm and this harm could be avoided by
disclosing the information; the conﬁdentiality can be
breached only as a last resort when all trials to convince
the patient to pass on the information by himself, have
failed’. Similarly, WHO (1998) considers that, ‘especially
when a serious burden can be avoided’, ‘(...) counselors
should inform people that genetic information may be
useful to their relatives and may invite individuals to ask
the relatives to seek genetic counseling. If the individual
refuses, particularly in cases where effective and afford-
able treatment or preventative measures are available,
the counselor may ethically make direct contact with the
relatives, bearing in mind that the information provided
should concern only their own genetic risk, not the
genetic status nor the identity of the relative who refused
to inform them.’
At the national level, numerous guidelines support the
disclosure of genetic information to family members
without the patient’s consent under similar exceptional
circumstances: Australia: CCV&NHMRC (1997, 1999),
AMA (2004); Canada: SCC (1991), CMA (1996),
CCHOTA (1999), CMA (2000), RMGA (2000); Ger-
many: GSHG (1996, 2001); Japan: JSHG (1994, 1995);
Netherlands (1989); the United Kingdom: BMA (1998),
GIG (1998), NCB (2000), HGC (2002), Joint Committee
on Medical Genetics (2003) and the United States of
America: ASHG/ACMG (1995), NHGRI (1997) ASHG
(1998).
Disclosure without patient’s consent under special
considerations
Several guidelines have addressed the issue of disclosure
of genetic information to family members without
patient’s consent under particular perspectives, or have
added special considerations and conditions to the
exceptional circumstances described above.
In ﬁrst place, several organizations do not preclude
the disclosure of genetic information to family members
without the patient’s consent but ultimately refer to
national laws. UNESCO (1997, 2004) clearly states that
‘limitations to the principles of consent and conﬁdenti-
ality may only be prescribed by law’ and that any
disclosure of genetic information without the individ-
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ual’s consent could only occur for ‘an important public
interest reason in cases restrictively provided for by
domestic law consistent with the international law of
human rights’. Similarly, the Council of Europe (1992
and [25]) recognizes that consideration should be given
to informing family members of their genetic risks, in
particular to avoid any prejudice to their health. How-
ever, such a communication could only take place if it is
provided for by national law or ‘in accordance with
national legislation’. Such positions are also supported
by some national bodies such as, for example, the
Canadian Medical Association in its Information Privacy
Code (1998) and the Australian National Health and
Medical Research Council (2000) which allows disclo-
sure of genetic information to family members without
the patient’s consent in exceptional circumstances but
ultimately stress that there is no such obligation in
Australian legislation and that before breaching conﬁ-
dentiality, health providers should consider the potential
for professional censure or legal action.
Other instances did not choose to take an explicit
position on this issue. HUGO (1996), for instance, states
that ‘special consideration should be given to the actual
or potential interests of family members’. Consequently,
the need for practical guidance, further research, more
speciﬁc regulations or legislation is often stressed by
other organizations. In 2001, the Temporary Committee
on Human Genetics and Other New Technologies of
Human Medicine of the European Parliament recom-
mended the creation of an appropriate legislation to sort
out such issues. The European Commission (2004)
recently concluded that ‘there is a need for clear
guidance acceptable to all parties involved (...) on how
to handle professional secrecy and the protection of
privacy’. Such a position is also shared by some national
bodies such as the Canadian Biotechnology Advisory
Committee (2001) or the Ontario Provincial Advisory
Committee on the New Predictive Genetic Technologies
(2001) which states that ‘further research should be
undertaken to determine whether disclosing genetic
information to high-risk relatives against an individual’s
wishes should be allowed’. More explicitly, the Danish
Council of Ethics (2001) recently recommended that ‘for
groups of diseases presenting the same hereditary
succession and ethical problems, descriptions be formu-
lated of the practice considered to be the good,
professional standard in force, and that these overall
guidelines accommodate a stance on the question of the
conditions governing the disclosure of genetic informa-
tion to another person’.
Certain recommendations (HUGO (1996, 1998),
WMA (1995), HGSA (1999), JSHG (2001)) have mainly
focused on the potential right of family members to have
access to the genetic information of their relatives and
not on the potential obligation of physicians to disclose
information without the patient’s consent. The right to
access genetic information of one’s relatives must be
clearly distinguished from a duty to warn. Indeed, a
duty to warn does not involve an actual request of a
family member to know about his genetic risks. There-
fore, recommendations on the right to access genetic
information of one’s relatives do not provide us with
practical guidance for the disclosure of genetic infor-
mation to family members who have not expressed their
will to know about their risks.
Discussion
Most of the guidelines issued by professional organiza-
tions and governmental advisory agencies are also
directed to this end. When the penalty for ignorance
has had serious damage, courts have leaned toward the
right to know and away from the right to conﬁdentiality.
This indicates that a duty to warn by physicians to family
members of the presence of a genetic disease in a patient
might evolve as a reasonable behaviour to prevent a
serious and foreseeable harm. For Lemmens and Austin
[26], ﬁnding a duty to warn the family members on the
physician means that we recognize an indirect harm
caused to potentially aﬀected family members. The
breach of the duty to warn may result in a subsequent
injury, such as impairment of the right to decide whether
to beneﬁt a medical surveillance, to modify life habits, or
to have oﬀspring.
Nevertheless, commentators differ on whether a duty
to warn when genetics information is involved is a
negative or positive development. Generally, the view is
that the conﬁdentiality of genetic information should be
given absolute protection and should never be breached
without the consent of the patient, even if the passing on
of the information would enable others to protect
themselves from the risk of harm. A study conducted
by Falk et al. [8] reveals that although 69% of medical
geneticists believe they bear responsibility to warn their
patients’ relatives when found to be at-risk for genetic
disease and 25% who faced the dilemma of a patient
refusing to notify their at-risk relatives seriously
considered disclosure without patient consent, only four
respondents proceeded to warn at-risk relatives of their
status. In another study, 46% of genetic counselors have
had a patient refuse to notify an at-risk relative: 21%
seriously considered warning at-risk relatives without
patient consent but only one genetic counselor did go on
to disclose [7].
According to Mertz et al. [27], control of information
about oneself is a fundamental embodiment of privacy,
and conﬁdentiality is the backbone of the provider–
patient trust relationship. Also, there may be signiﬁcant
numbers of individuals who do not want to know that
they are at risk [28; 29; 30]. Other commentators have
argued that the imposition of a duty to warn is unwise
since the patient has not deliberately ‘created’ a genetic
risk and a harm for the relatives. Lemmens and Austin
[26] explain that it is a ‘preexisting’ risk that is suddenly
identiﬁed because of newly acquired knowledge of
genetic information. The risk is not so much related
to something external to the other persons. Moreover,
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with rare exception, asymptomatic genetic conditions
do not hold the prospect of imminent harm; while the
course of infectious disease exhibits relative uniformity
and predictability, genetic conditions, most of which are
multifactorial, are marked by substantial variability,
burdening genetic prediction with considerable uncer-
tainty. Another argument is that the physician cannot
presume to have complete and accurate information
about the patient’s family history and interpersonal
dynamics, about how information may be received by
his relatives. In some cases, providing genetic informa-
tion to family members could do more harm than good.
Yet an emerging view is that it may be permissible to
breach medical conﬁdentiality in order to protect
another from serious harm (Table 1). Such an approach
is based on the notion that a family member owes a
moral duty of care to the family members of the patient
and when that duty is not exercised, the physician may
breach conﬁdentiality and warn at-risk relatives [31].
Physicians are expected to seek to do good for their
patients; this is described as the principle of beneﬁcence.
Beauchamp and Childress [32] have stated that this
principle can apply for warning at-risk relatives in the
following circumstances: (1) that the person to be
helped is at signiﬁcant risk of harm; (2) that help from
the person faced with the choice is needed to prevent
that risk materializing; (3) that there is a high proba-
bility that their help will prevent the harm; (4) that
helping would not present signiﬁcant risks, costs or
burdens to the person asked to help; (5) that the beneﬁt
for the person to be helped outweighs the costs or
burdens to the person asked to help. Studies have
shown that most patients do consent to disclosure after
considering these arguments [3,33,1,2,12,34]. In a study
conducted by Clarke et al. [3] on the attitudes towards
disclosure, only 65 patients out of nearly 40 000
surveyed over a period of 12 months refused to warn
their relatives. Thus, 39 parents refused to inform their
adult children of a potential genetic risk; 32 children or
relations were not informed, as well as 4 spouses. A fear
that the information might cause anxiety for relatives
was the reason most frequently cited in justifying non-
disclosure. In contrast, concerns for conﬁdentiality and
privacy were rarely invoked. In another study relative to
genetic testing for hereditary colon cancer, 78% of
relatives thought it acceptable to have the genetic
information brought to their attention, the remaining
22% did not mind being approached with the informa-
tion and 91% decided to take the genetic test [2].
The tendency towards a family and community-ori-
ented approach, supported by the Human Genome
Research Project encourages a shift from ‘individual
therapy’ to a ‘family-and-future-generation oriented’ one
[66]. It is necessary however, that this shift does not
overstep the principles of individual will, responsibility
and self-determination. A duty of physicians to disclose
the presence of a genetic disease to relatives of their
aﬀected patients has been recognized when the disease is
fatal if diagnosed late but curable if diagnosed early. This
was the case inPate. By contrast, if the disease is incurable
and even untreatable, the duty would be tenuous, except
for reproductive decisions.For instance, the International
Huntington Association [35] was not in favour of such a
duty. Some diseases would ﬁt in-between, such as hered-
itary breast cancer, which is treatable by prophylactic
surgery. Thus, policies for disclosure should be developed
with caution and in considering the following facts: (1) the
patient; (2) the accuracy of the genetic test; (3) the disease
and (4) the relative [36]. If the genetic test is not accurate
and the disease is not fatal, or treatable and with a high
degree of genetic penetrance, disclosure serves little
purpose, other than to aid the relative inmaking informed
reproductive decisions [36]. Consequently, it has been
recommended that individual cases should be based on
speciﬁc facts and that the disclosure should be limited to
the minimum extent needed to prevent harm [37].
Regarding the patient, some authors recommend
asking the patient’s consent in advance of the genetic
testing for permission to disclose genetic information to
relatives [36, 11; 24]. Seeking the consent of the patient
preserves his autonomy and allows physicians to explain
to him why they think that disclosure might be important
in some circumstances. For instance, in Denmark, the
law does not authorize physicians to directly transmit
genetic information to relatives but accepts such a
physician’s disclosure on a patient’s request. Patients
may be asked to disclose the identities of family members
to a physician to ensure diﬀusion of genetic risk
information within aﬀected families. The identity of the
patient is disclosed to relatives on request if consent has
been given by the patient [12]. Wilcke et al. [12] have
shown a strong consensus on the position that the patient
ought to disclose the identity of relatives to enable the
physician to oﬀer them genetic testing. The authors
explain the lack of concern about one’s own right to
privacy by the need of sick persons for family support
and to achieve such family support, it seems crucial to
maintain openness about the disease in the family.
Regarding the relative, there still remain the risks of
harming those who do not want to know. It has been
stated that ‘the harm caused by disclosure should not
outweigh the harm for which the family members would
be exposed to by non-disclosure [38]. Or, disclosure
‘could perhaps be justiﬁed if the potential harm to the
relative of not being informed, and the beneﬁts of being
informed, outweigh the potential harm to the index case
of conﬁdentiality being broken’ [11]. Legal cases indicate
that it is unlikely to see a jury awarding great damages
to a patient because the doctor warned a relative about a
genetic condition that the patient did not want them to
know about.
A reasonable approach calls for a case-by-case
determination of whether the beneﬁts and harms of
disclosure outweigh the beneﬁts and harms of protecting
conﬁdentiality. Such an approach is advocated by the
American Society of Human Genetics (ASHG) Social
Issues Subcommittee on Familial Disclosure [39]. The
ASHG stated that when a patient refuses to inform
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relatives, rather than imposing a ﬁrm duty to warn at-
risk relatives or an absolute duty of conﬁdentiality,
policy should make room for the exercise of sound
professional judgment to weight and measure the
interests and values at stake. More recently, more
detailed advice concerning the duty to warn relatives
has been established, urging physicians to assist patients
in their communication with relatives. In its policy
update on genetic testing for cancer susceptibility, the
American Society of Clinical Oncology states that ‘the
cancer care provider’s obligations (if any) to at-risk
relatives are best fulﬁlled by communication of familial
risk to the person undergoing testing, emphasizing the
importance of sharing this information with family
members so that they may also beneﬁt’ (2003). This view
is reaﬃrmed by the American Medical Association Code
of Medical Ethics (2004): physicians ‘should make
themselves available to assist patients in communicating
with relatives to discuss opportunities for counseling
and testing, as appropriate.’
As the availability of tests to identify hereditary
predispositions continues to grow, some authors propose
that a plan should be formulated to initiate contact with
family members and to provide a framework for coun-
seling and guidance [31; 40; 41]. Delay et al. [33] have
developed a communication skills-building intervention
for providing the patients with skills for communicating
genetic test results to their relatives. The six-step com-
munication counseling intervention addresses the impor-
tant questions of whom to tell, what to tell, and how to
tell, whereas a Genetic Resource Handbook oﬀers the
proband reference materials and ﬂexibility in tailoring
her/his messages to the emotional needs and educational
and interest levels of her family. Two other models have
been imagined in which the patient is the primary
provider of information within the family but has the
assistance of health care practitioners in presenting and
explaining information as the patient and his or her
family deem appropriate; such a model might alleviate
the potential conﬂict between the wishes of the patient
and the physician’s obligation to third parties [40; 41].
These models can be found in the ASCO [42] and [43]
recommendations. Finally, in the joint account model
elaborated by Parker and Lucassen [44], it is assumed
that genetic information should be available to all
account holders (health professionals, relatives) unless
there are good reasons to do otherwise. The justiﬁcations
in favour of a joint account must adhere to the ethical
principles of justice and reciprocity; there must also be
beneﬁts to be gained by sharing genetic information.
Seeing as geneticists work with families, the chosen
approach must be consistent with the very nature of
practice in genetics.
Conclusion
Although the duty of a physician regarding disclosure of
genetic information to a patient’s relatives has only been
addressed by a few legal cases, courts have found such a
duty under some circumstances. Generally, disclosure
should not be permitted without the patient’s consent.
Yet, due to the nature of genetic information, exceptions
are foreseen, where treatment and prevention are
available. This duty to warn a patient’s relative is also
supported by some professional and policy organiza-
tions that have addressed the issue. Moreover, practice
guidelines with a communication and intervention plan
are emerging, providing physicians with tools that allow
them to assist patients in their communication with
relatives without jeopardizing their professional liability.
Medical advances will result in an increasing number
of individuals who know that they have a genetic disease
that they can transmit to offspring, and a related
number of physicians who know of the existence of such
a disease in their patients and thus in their patients’
relatives. There is no doubt that genetic information will
lead to the recognition of new duties of health care
professionals in the future. This could also lead to a
social change within families where there would be a
greater openness towards sharing medical information.
The current socio-cultural context and pressures of
the ‘promise’ of genetic information cannot be ignored.
However, it would be fair if there was transparency
about the grounds of the decision to warn a patient’s
relatives. Appealing to rationales that all can accept as
relevant to meet health needs fairly, it would allow
procedures for revising decisions in the light of chal-
lenges to them.
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weighs the potential beneﬁts to the relative of being informed.
Conversely, disclosure without the index case’s permission could
perhaps be justiﬁed if the potential harm to the relative of not
being informed (and the beneﬁts of being informed), outweighs
the potential harm to the index case of conﬁdentiality being bro-
ken.’
45. Nuﬃeld Council on Bioethics (NCB), Genetic Screening: Ethical
Issues, 2000: ‘When genetic screening reveals information that
may have serious implications for relatives of those who have
been screened, health professionals should explain why the infor-
mation should be communicated to other family members. The
Council recommends that in such circumstances health profes-
sionals should seek to persuade individuals, if persuasion should
be necessary, to allow the disclosure of relevant information to
other family members. They should also seek to ensure that
treatment, counselling and other appropriate support are made
available to those to whom such unsought information is dis-
closed. Both the law and professional guidelines provide for
exceptional circumstances, when an individual cannot be per-
suaded to inform family members with a legitimate right to
know. In such exceptional circumstances the individual’s desire
for conﬁdentiality may be overridden. The decision can only be
made case by case.’
46. American Society of Clinical Oncology (ASCO), Policy State-
ment Update: Genetic Testing for Cancer Susceptibility, Journal
of Cinical Oncology, Vol. 21, No 12 (June 15), 2003.
47. American Medical Association (AMA), Report of the Council
on Ethical and Judicial Aﬀairs, Disclosure of Familial Risk in
Genetic Testing, CEJA Report 9-A-03, 2003.
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48. National Society of Genetic Counselors, National Society of Ge-
netic Counselors’ Statement: Conﬁdentiality of test results,
Adopted 1991, revised 2002: ‘It is the right and responsibility of
the individual to determine who shall have access to his/her own
medical information, including genetic information’.
49. Great Lakes Regional Genetic Group (GLRGG), The Evalua-
tion of Clinical Services Subcommittee, Minimum Guidelines for
the Delivery of Clinical Genetic Services, 1993.
50. American President’s Commission for the Study of Ethical Prob-
lems in Medicine and Biomedical and Behavioural Research,
1983.
51. Institute of Medicine, Committee on Assessing Genetic Risks,
Assessing Genetic Risks - Implications for Health and Social Pol-
icy, 1994.
52. American College of Medical Genetics & American Society of
Human Genetics, Ethical, Legal and Psychosocial Implications of
Genetic Testing in Children and Adolescents, 1995, http://genet-
ics.faseb.org/genetics/acmg/pol-13.htm: ‘Although the provider
might presume an obligation to inform other family members at
risk, some patients may prefer not to inform other family mem-
bers. Current recommendations [22] and practices [23] suggest
that the patient’s wishes for conﬁdentiality should be respected
as long as the failure to disclose genetic information is not likely
to result in immediate serious physical harm to the relative.’
53. American Society of Human Genetics, Social Issues Subcommit-
tee on Familial Disclosure, Statement: Professional disclosure of
familial genetic information, 1998.
54. National Human Genome Research Institute, ELSI, Promoting
Safe and Eﬀective Genetic Testing in the United States – Final
Report of the Task Force on Genetic Testing, 1997: http://
www.genome.gov/10002405: ‘Health care providers have an obli-
gation to the person being tested not to inform other family
members without the permission of the person tested, except in
extreme circumstances.’
Notes
1. Gentechnikgesetz (GTG; Gene Technology Act), BGBl. Nr. 510/
1994, amended in 1998 (BGBl. I Nr. 73/1998), and in 2002
(BGBl. I Nr. 94/2002.
2. Genetic Information Law, 5761–2000 (13 December 2000).
3. Many states in America have enacted legislation restricting the
use of genetic information by health insurers and in employ-
ment. Some states even prohibit communication of genetic
information to anyone without the permission of the person
tested [43]. However, there is currently no comprehensive fed-
eral legislation that protects the right to privacy of individu-
ally identiﬁable health care information in the United States
of America [16].
4. The Personal Data Protection Act, 2000, also deals speciﬁcally
with genetic information.
5. The Manitoba Personal Health Information Act, 1997, explicitly
states that the deﬁnition of ‘health information’ includes genetic
information.
6. The Amendment of the Federal Constitution [45] states that, in
regard to genetics and assisted procreation, the genetic heritage
of a person may only be analysed, recorded, and disclosed with
that person’s consent, or on the basis of a legal provision.
7. Some countries are currently considering legal reforms and
new laws in this ﬁeld. For instance: Switzerland (Bill regarding
Genetic Testing on Humans, 1998, approved by the Federal
Council in September 2002, FF 02.065, 6841), United States
(Genetic Information Nondiscrimination Act of 2003, S. 1053,
approved by the Senate in November 2003), Australia (see
ALRC 96, 2003),
8. Tarasoﬀ v. The Regents of the University of California, 131 Cal.
Rptr. 14 (Sup. Ct. 1976) [hereinafter Tarasoﬀ]. In this case, the
California Supreme Court ruled against a psychiatrist who did
not warn a third party of his patient’s harmful intent.
9. Other examples include a physician’s duty to warn a third party
who may be at foreseeable risk for contracting a sexually trans-
mitted or communicable disease, and a case of a physician’s duty
to a third party who was injured by the physician’s epileptic pa-
tient who had a seizure while driving.
10. In the Pate case, the plaintiﬀ was receiving treatment for medul-
lary thyroid carcinoma and sued the physician who had previ-
ously treated her mother for the same condition, but with whom
the plaintiﬀ had no patient–physician relationship. The plaintiﬀ
alleged that the physician failed to warn the mother that her
condition could be genetically transmitted and that her children
should be tested [4]. The Safer case involved a suit by a plaintiﬀ
against the estate of a physician who had treated the plaintiﬀ’s
father for multiple polyposis with adenocarcinoma of the colon
30 years earlier. At the time of the father’s death caused by met-
astatic cancer, the plaintiﬀ was 10 years old. At age 36, the
plaintiﬀ was diagnosed with cancerous blockage because of mul-
tiple polyposis of the colon with evidence of metastatic disease.
The cause of action against the physician was for professional
negligence, alleging that multiple polyposis is a hereditary condi-
tion that, if undiscovered or untreated, invariably leads to meta-
static colorectal cancer [5]. In the Molloy case, the plaintiﬀ
proceeded with a lawsuit against the physicians who had treated
her daughter more than 10 years earlier. In this case, Kimberly
Molloy claimed that the physicians failed to inform her and her
second husband about future risks due to a hereditary form of
mental retardation, fragile X syndrome, present in her ﬁrst
daughter. In this case, which stems more from an alleged failure
to perform a diagnostic test than from a failure to breach conﬁ-
dentiality to warn of a genetic disease, the mother and her sec-
ond husband stated they would not have conceived another
child if they had known of the diagnosis of fragile X syndrome
in the mother’s ﬁrst child [46].
11. In Austria, the Gene Technology Act (1994) explicitly states that
‘the physician responsible for genetic testing shall (...) recom-
mend to the person undergoing testing that he advises those
members of his family likely to be aﬀected to undergo genetic
testing and counseling’. Thus, in this respect, the Austrian physi-
cian may fulﬁll his duty to warn by notifying his patients of the
genetic risks to his blood relatives and it belongs to the patient
only to disseminate the information within his family.
12. French legislation – which does not speciﬁcally deals with genetic
information – seems to prohibit any direct disclosure of genetic
information to a third party, including patient’s family members
in any circumstance [47].
13. Australia [48], Switzerland, Canada (Manitoba), Israe¨l.
14. De´cret no 95–1000 du 6 septembre 1995 portant code de de´on-
tologie me´dicale, art. 51.
15. National Bioethics Commission, Recommendation on the collec-
tion and use of genetic data, Greece, September 2002. http://
www.bioethics.gr/mod/userpage/images/opinion%20in%20en-
glish.pdf
16. The GAIEB has become the European Group on Ethics in Sci-
ence and New Technologies (EGE) since 1997.
17. The committee gave the example of malignant hypothermia, a
genetic disease that can cause a fatal reaction to common anaes-
thetics.
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